PHI density prospectively improves prostate cancer detection - Takeaways - MDSpire

PHI density prospectively improves prostate cancer detection

  • By

  • Carsten Stephan

  • Klaus Jung

  • Michael Lein

  • Hannah Rochow

  • Frank Friedersdorff

  • Andreas Maxeiner

  • January 20, 2021

  • 0 min

Share

  • 1

    Prostate Health Index (PHI) has been established as a biomarker for prostate cancer (PCa) detection since its FDA approval in 2012.

  • 2

    PHI density (PHID) was proposed in 2014 and has shown potential to improve PCa detection compared to PHI in some studies.

  • 3

    In a prospective study with over 1000 men, PHID demonstrated a higher area under the curve (AUC) for PCa detection than PHI.

  • 4

    PHID outperformed traditional markers like PSA and percent free PSA (%fPSA) in detecting clinically significant PCa.

  • 5

    Despite some studies showing PHID's advantages, results vary, and no significant differences were found in specific patient subgroups.

Original Source(s)

PHI density prospectively improves prostate cancer detection

  • by Carsten Stephan, Klaus Jung, Michael Lein, Hannah Rochow, Frank Friedersdorff, Andreas Maxeiner

  • January 20, 2021

Related Content

Do we need MRI in all biopsy naïve patients? A multicenter cohort analysis

Contemporary options and future perspectives: three examples highlighting the challenges in testicular cancer imaging

Predicting invasiveness and disease-specific survival in upper tract urothelial carcinoma: identifying relevant clinical tumour characteristics